RxDoctor Payments Data

Monica Valerio, NP

Family · Burgettstown, PANPI 1679991723

Payments from drug & device makers

$7,080in general payments, 2019–2025

Across 390 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$640
  • Novartis$501
  • Lexicon Pharmaceuticals, Inc.$424
  • Amgen$397
  • Bayer$394
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,00499%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,080 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,516
Medicare patients
46
Services billed
1,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$45,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,253
EntrestoSacubitril/Valsartan32$18,850
JanuviaSitagliptin Phosphate16$16,180
TrulicityDulaglutide15$14,222
MounjaroTirzepatide13$13,728
FarxigaDapagliflozin Propanediol12$13,489
OzempicSemaglutide14$13,172
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$12,763
XareltoRivaroxaban22$12,055
LinzessLinaclotide16$9,094
Ranolazine ErRanolazine18$2,164
Metoprolol Succinate122$1,614
Potassium Chloride63$1,478
Pantoprazole Sodium74$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$176$45,80061 claims
Lilly USA, LLCTrulicity, Mounjaro$151$27,95028 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,170$26,25229 claims
GSKTrelegy Ellipta$20$19,25329 claims
NovartisEntresto$501$18,85032 claims
MerckJanuvia$335$16,18016 claims
Novo NordiskOzempic$295$13,17214 claims
Johnson & JohnsonXarelto$214$12,05522 claims
AbbVieLinzess$153$9,09416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Burgettstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →